Reports Q4 revenue $86.6M, consensus $84.56M. “2024 was a transformative year for CareDx (CDNA), positioning the company for long-term profitable growth,” said John W. Hanna, CareDx President and CEO. “We look forward to another year of strong performance in 2025, driven by our focus on testing services volume growth, expansion of payer coverage, and operational excellence as we scale our business.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- CareDx reports District Court reverses jury decision in patent infringement case
- CDNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- CareDx announces AlloSeq cfDNA study data published in Transplant International
- Wells Fargo upgrades CareDx to Equal Weight on improved risk/reward
- CareDx upgraded to Equal Weight from Underweight at Wells Fargo